Cécile Alanio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cécile Alanio has a total of 659 co-authors. Here are the top co-authors by number of shared publications:
Katelyn T. Byrne
35 shared publicationsE. John Wherry
Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology and Immune Health, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
34 shared publicationsAna P. Ferreira
33 shared publicationsAndreanne M. Lacroix
33 shared publicationsAndressa Dias Costa
33 shared publicationsAustin P. Huffman
33 shared publications
Latest Publications
- Open Access
Integration of clinical and T-cell immune profiling to predict early response to CD3xBCMA bispecific antibody immunotherapy in Multiple Myeloma
The emergence of bispecific antibodies (BsAbs) targeting T cells (CD3+) and tumor plasma B cells (BCMA+) has provided a new therapeutic option for patients with relapsed/refractory multiple myeloma cancer. However, responses to CD3xBCMA BsAb therapy remain heterogeneous, and treatment is associated with frequent immune-related adverse events. Although baseline immune characteristics have been associated with clinical outcomes, little is known about the early immune dynamics induced by this therapy. Here, we investigated whether longitudinal clinical monitoring and high-dimensional profiling of blood circulating T cells could identify early biomarkers of response or toxicity during treatment. Our results indicate that all treated patients exhibit an early depletion of circulating T cells associated with T-cell activation within the first two weeks. Integration of clinical and immunological parameters using Factorial Analysis of Mixed Data (FAMD) identified immune features associated with treatment outcome. Responders had lower plasma soluble BCMA concentrations, fewer bone lesions, higher circulating lymphocyte counts at baseline. During the first days of treatment, responders exhibited a more pronounced increase in plasma CXCL10 levels, associated with a greater decrease in T lymphocyte counts. Overall, our findings suggest that integrating clinical and immune parameters measured during the first days of treatment may enable early patient stratification and support the development of a predictive score to identify patients with multiple myeloma who are most likely to benefit from CD3xBCMA BsAb therapy.
Open AccessIntegration of clinical and T-cell immune profiling to predict early response to CD3xBCMA bispecific antibody immunotherapy in Multiple Myeloma
The emergence of bispecific antibodies (BsAbs) targeting T cells (CD3+) and tumor plasma B cells (BCMA+) has provided a new therapeutic option for patients with relapsed/refractory multiple myeloma cancer. However, responses to CD3xBCMA BsAb therapy remain heterogeneous, and treatment is associated with frequent immune-related adverse events. Although baseline immune characteristics have been associated with clinical outcomes, little is known about the early immune dynamics induced by this therapy. Here, we investigated whether longitudinal clinical monitoring and high-dimensional profiling of blood circulating T cells could identify early biomarkers of response or toxicity during treatment. Our results indicate that all treated patients exhibit an early depletion of circulating T cells associated with T-cell activation within the first two weeks. Integration of clinical and immunological parameters using Factorial Analysis of Mixed Data (FAMD) identified immune features associated with treatment outcome. Responders had lower plasma soluble BCMA concentrations, fewer bone lesions, higher circulating lymphocyte counts at baseline. During the first days of treatment, responders exhibited a more pronounced increase in plasma CXCL10 levels, associated with a greater decrease in T lymphocyte counts. Overall, our findings suggest that integrating clinical and immune parameters measured during the first days of treatment may enable early patient stratification and support the development of a predictive score to identify patients with multiple myeloma who are most likely to benefit from CD3xBCMA BsAb therapy.
- Open Access
The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Impact of chronic viral infection on the CD8 preimmune repertoire : when do we lose our naivety ?
Impact d'une infection virale chronique sur le répertoire T CD8 préimmun : à quel moment perd-on sa naiveté?: Le répertoire T CD8 préimmun correspond aux lymphocytes T spécifiques d'antigène circulant en périphérie, et n'ayant pas encore été activés. Ces cellules sont très rares, et de ce fait, n'ont jusqu'ici pas pu être étudiées de façon approfondie. Nous avons dans un premier temps développé un protocole d'enrichissement basé sur la technologie des tétramères. Nous avons pu détecter et énumérer des lymphocytes T CD8 naïfs spécifiques d'antigènes dans le sang de sujets sains. Nous avons ensuite utilisé cet outil pour évaluer le répertoire T préimmun de patients chroniquement infectés par le virus de l'hépatite C (cHCV). Nous avons démontré que celui-ci est significativement perturbé, avec des cellules hypersensibles à l'activation TCR et une proportion importante de lymphocytes T de phénotype mémoire alors qu'ils n'ont pourtant pas rencontré leur antigène cible. Ces anomalies disparaissent après résolution de l'infection, soulignant l'intérêt d'instaurer précocément un traitement antiviral chez ces patients. Enfin, nous avons observé dans un modèle de souris transgéniques (OTI) une proportion importante de T inexpérimentés de phénotype mémoire chez les animaux non-immunisés déficients en cxcr3. Nos travaux démontrent que les lymphocytes T inexpérimentés peuvent perdre leur naïveté dans différentes situations pathologiques. Ces résultats devraient être pris en considération pour l'optimisation de futures stratégies d'immunothérapie, notamment lorsque des patients dits "inflammatoires" sont la cible de vaccinations. Enfin, nos résultats soulignent la difficulté d'interpréter les données d'immunophénotypage en l'absence d'information sur la spécificité antigénique.
- 1 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Impact of chronic viral infection on the CD8 preimmune repertoire : when do we lose our naivety ?
Impact d'une infection virale chronique sur le répertoire T CD8 préimmun : à quel moment perd-on sa naiveté?: Le répertoire T CD8 préimmun correspond aux lymphocytes T spécifiques d'antigène circulant en périphérie, et n'ayant pas encore été activés. Ces cellules sont très rares, et de ce fait, n'ont jusqu'ici pas pu être étudiées de façon approfondie. Nous avons dans un premier temps développé un protocole d'enrichissement basé sur la technologie des tétramères. Nous avons pu détecter et énumérer des lymphocytes T CD8 naïfs spécifiques d'antigènes dans le sang de sujets sains. Nous avons ensuite utilisé cet outil pour évaluer le répertoire T préimmun de patients chroniquement infectés par le virus de l'hépatite C (cHCV). Nous avons démontré que celui-ci est significativement perturbé, avec des cellules hypersensibles à l'activation TCR et une proportion importante de lymphocytes T de phénotype mémoire alors qu'ils n'ont pourtant pas rencontré leur antigène cible. Ces anomalies disparaissent après résolution de l'infection, soulignant l'intérêt d'instaurer précocément un traitement antiviral chez ces patients. Enfin, nous avons observé dans un modèle de souris transgéniques (OTI) une proportion importante de T inexpérimentés de phénotype mémoire chez les animaux non-immunisés déficients en cxcr3. Nos travaux démontrent que les lymphocytes T inexpérimentés peuvent perdre leur naïveté dans différentes situations pathologiques. Ces résultats devraient être pris en considération pour l'optimisation de futures stratégies d'immunothérapie, notamment lorsque des patients dits "inflammatoires" sont la cible de vaccinations. Enfin, nos résultats soulignent la difficulté d'interpréter les données d'immunophénotypage en l'absence d'information sur la spécificité antigénique.
- Open Access
CMV seropositivity associates with poor clinical outcome in triple negative breast cancer
- Open Access
- 11 June 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (9) , 3205
Author Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
- 11 June 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (9) , 3205
Open AccessAuthor Correction: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
- Top Cited Papers
- 1 June 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (8) , 2778-2787
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
Glioblastoma (GBM) is the most common primary brain cancer in adults and carries a median overall survival (OS) of 12–15 months. Effective therapy for recurrent GBM (rGBM) following frontline chemoradiation is a major unmet medical need. Here we report the dose escalation and exploration phases of a phase 1 trial investigating intracerebroventricular delivery of bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) epitope 806 and interleukin-13 receptor alpha 2 (IL-13Rα2), or CART-EGFR-IL13Rα2 cells, in patients with EGFR-amplified rGBM. Primary endpoints included dose-limiting toxicity, determination of the maximum tolerated dose and recommended dose for expansion, and occurrence of adverse events. Secondary endpoints included objective radiographic response, duration of response, progression-free survival and OS. A total of 18 patients received CART-EGFR-IL13Rα2 cells. The maximum tolerated dose was determined to be 2.5 × 107 cells. Of the 18 patients, 10 (56%) experienced grade 3 neurotoxicity; none had grade 4–5 neurotoxicity. Of 13 patients, 8 (62%) with measurable disease at the time of CAR T cell infusion experienced tumor regression, with one confirmed partial response by Modified Response Assessment in Neuro-Oncology criteria (objective radiographic response, 8%; 90% confidence interval, 0–32%) and one patient with ongoing durable stable disease lasting over 16 months. Median progression-free survival was 1.9 months (90% confidence interval, 1.1–3.4 months), and median OS was not yet reached at the time of data cut-off (median follow-up time, 8.1 months). These findings indicate that intracerebroventricular delivery of bivalent CART-EGFR-IL13Rα2 is feasible and appears safe. CART-EGFR-IL13Rα2 cells are bioactive and exhibit a signal of antitumor effect in rGBM. ClinicalTrials.gov registration: NCT05168423.
- 1 June 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (8) , 2778-2787
Top Cited PapersIntracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
Glioblastoma (GBM) is the most common primary brain cancer in adults and carries a median overall survival (OS) of 12–15 months. Effective therapy for recurrent GBM (rGBM) following frontline chemoradiation is a major unmet medical need. Here we report the dose escalation and exploration phases of a phase 1 trial investigating intracerebroventricular delivery of bivalent chimeric antigen receptor (CAR) T cells targeting epidermal growth factor receptor (EGFR) epitope 806 and interleukin-13 receptor alpha 2 (IL-13Rα2), or CART-EGFR-IL13Rα2 cells, in patients with EGFR-amplified rGBM. Primary endpoints included dose-limiting toxicity, determination of the maximum tolerated dose and recommended dose for expansion, and occurrence of adverse events. Secondary endpoints included objective radiographic response, duration of response, progression-free survival and OS. A total of 18 patients received CART-EGFR-IL13Rα2 cells. The maximum tolerated dose was determined to be 2.5 × 107 cells. Of the 18 patients, 10 (56%) experienced grade 3 neurotoxicity; none had grade 4–5 neurotoxicity. Of 13 patients, 8 (62%) with measurable disease at the time of CAR T cell infusion experienced tumor regression, with one confirmed partial response by Modified Response Assessment in Neuro-Oncology criteria (objective radiographic response, 8%; 90% confidence interval, 0–32%) and one patient with ongoing durable stable disease lasting over 16 months. Median progression-free survival was 1.9 months (90% confidence interval, 1.1–3.4 months), and median OS was not yet reached at the time of data cut-off (median follow-up time, 8.1 months). These findings indicate that intracerebroventricular delivery of bivalent CART-EGFR-IL13Rα2 is feasible and appears safe. CART-EGFR-IL13Rα2 cells are bioactive and exhibit a signal of antitumor effect in rGBM. ClinicalTrials.gov registration: NCT05168423.
- Open Access
- 9 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (19) , eadu8811
Structural basis for hepatitis E virus neutralization by potent human antibodies
Antibodies targeting the hepatitis E virus (HEV) surface capsid protein (CA) are essential for infection control and resolution, yet their molecular and functional attributes remain largely elusive. We characterized 144 human HEV-CA–specific monoclonal antibodies cloned from the memory B cells of HEV-exposed individuals. Most human anti-CA antibodies cross-reacted with all HEV genotype variants, and a subset also recognized the zoonotic rat hepatitis E virus. HEV antibody repertoire was diverse and contained highly potent neutralizing antibodies binding to the CA protruding (P) domain. Structural analyses of CA protein complexed with three potent and broad HEV antibodies uncovered a neutralizing site located on monomeric P domain loops at the apex of the viral spike. These findings provide valuable insights into the protective humoral response to HEV and offer a framework for the rational design of HEV vaccines and immunotherapies.
- 9 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (19) , eadu8811
Open AccessStructural basis for hepatitis E virus neutralization by potent human antibodies
Antibodies targeting the hepatitis E virus (HEV) surface capsid protein (CA) are essential for infection control and resolution, yet their molecular and functional attributes remain largely elusive. We characterized 144 human HEV-CA–specific monoclonal antibodies cloned from the memory B cells of HEV-exposed individuals. Most human anti-CA antibodies cross-reacted with all HEV genotype variants, and a subset also recognized the zoonotic rat hepatitis E virus. HEV antibody repertoire was diverse and contained highly potent neutralizing antibodies binding to the CA protruding (P) domain. Structural analyses of CA protein complexed with three potent and broad HEV antibodies uncovered a neutralizing site located on monomeric P domain loops at the apex of the viral spike. These findings provide valuable insights into the protective humoral response to HEV and offer a framework for the rational design of HEV vaccines and immunotherapies.
- Open Access
- 31 May 2024
- Published by EDP Sciences in médecine/sciences
- Vol. 40 (5) , 445-453
Optimisation de l’efficacité et de la sécurité d’utilisation des lymphocytes CAR-T
Le système immunitaire joue un rôle déterminant dans le contrôle et l’éradication des tumeurs. Une meilleure compréhension des mécanismes en jeu a permis le développement des immunothérapies, et notamment des thérapies par lymphocytes CAR-T. Ces thérapies ont montré une grande efficacité dans les maladies hématologiques, mais leur application aux tumeurs solides nécessite des optimisations pour améliorer leur efficacité et leur sécurité. Ces ajustements permettront une plus grande applicabilité des lymphocytes CAR-T, non seulement pour les traitements anti-tumoraux mais aussi pour le traitement de maladies auto-immunes ou fibreuses.
- 31 May 2024
- Published by EDP Sciences in médecine/sciences
- Vol. 40 (5) , 445-453
Open AccessOptimisation de l’efficacité et de la sécurité d’utilisation des lymphocytes CAR-T
Le système immunitaire joue un rôle déterminant dans le contrôle et l’éradication des tumeurs. Une meilleure compréhension des mécanismes en jeu a permis le développement des immunothérapies, et notamment des thérapies par lymphocytes CAR-T. Ces thérapies ont montré une grande efficacité dans les maladies hématologiques, mais leur application aux tumeurs solides nécessite des optimisations pour améliorer leur efficacité et leur sécurité. Ces ajustements permettront une plus grande applicabilité des lymphocytes CAR-T, non seulement pour les traitements anti-tumoraux mais aussi pour le traitement de maladies auto-immunes ou fibreuses.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Figure S1 shows the CONSORT diagram.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Figure S1 shows the CONSORT diagram.
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Figure S4 shows the raw multiplex serum cytokine analysis data from Figure 4, and the antibody list and the gating strategy for the CyTOF analysis, all performed on the peripheral blood samples.
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Figure S4 shows the raw multiplex serum cytokine analysis data from Figure 4, and the antibody list and the gating strategy for the CyTOF analysis, all performed on the peripheral blood samples.